Natreon and pharma firm team up for diabetes project
New Jersey-based Natreon said it has developed the dietary platform for the product.
At a presentation at the 9th Annual Diabetes Technology Meeting in San Francisco this week the companies highlighted the product’s effect in rabbits, which they said is a well-established model for studying the oral absorption of compounds.
Dr Marco Prosdocimi, Chief Scientific Officer for Puredel and lead author of the study commented:
“The data to be presented clearly show that Ossulin delivers insulin efficiently, resulting in blood levels higher than those observed with other oral insulin products.”
Natreon's said its R&D staff in the US and India are working closely with Puredel to help facilitate the next stage of scientific validation prior to commercial development.
